<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886813/" ref="ordinalpos=2564&amp;ncbi_uid=5690746&amp;link_uid=PMC3886813" image-link="/pmc/articles/PMC3886813/figure/F2/" class="imagepopup">Figure 2. IL-6 family <span class="highlight" style="background-color:">signaling</span> through the JAK/STAT-3 <span class="highlight" style="background-color:">pathway</span>.  From: NF-?B and STAT3 <span class="highlight" style="background-color:">signaling</span> in glioma: targets for future therapies. </a></div><br /><div class="p4l_captionBody">OSM binding to the OSM receptor activates intracellular JAK kinases, predominantly JAK2, which phosphorylate (yellow circles) STAT-3. Once phosphorylated, STAT-3 molecules dimerize, translocate to the nucleus and bind to STAT response elements in the promoters of target genes. OSM: Oncostatin-M.</div></div>